International Journal of Cancer Management

Published by: Kowsar

CD44 Standard Isoform; Not a Good Marker for Colon Cancer

Pantea Rohani 1 , Farahnaz Noroozinia 1 , Parisa Modarresi 1 and Ata Abbasi 1 , *
Authors Information
1 Department of Pathology, Urmia University of Medical Sciences, Urmia, IR Iran
Article information
  • International Journal of Cancer Management: September 2017, 10 (9); e9166
  • Published Online: September 30, 2017
  • Article Type: Research Article
  • Received: September 27, 2016
  • Accepted: August 30, 2017
  • DOI: 10.5812/ijcm.9166

To Cite: Rohani P, Noroozinia F, Modarresi P, Abbasi A. CD44 Standard Isoform; Not a Good Marker for Colon Cancer, Int J Cancer Manag. 2017 ; 10(9):e9166. doi: 10.5812/ijcm.9166.

Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Zavrides HN, Zizi-Sermpetzoglou A, Panousopoulos D, Athanasas G, Elemenoglou I, Peros G. Prognostic evaluation of CD44 expression in correlation with bcl-2 and p53 in colorectal cancer. Folia Histochem Cytobiol. 2005; 43(1): 31-6[PubMed]
  • 2. Banky B, Raso-Barnett L, Barbai T, Timar J, Becsagh P, Raso E. Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression. Mol Cancer. 2012; 11: 83[DOI][PubMed]
  • 3. Mulder JW, Wielenga VJ, Polak MM, Van den Berg FM, Adolf GR, Herrlich P, et al. Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorogenesis. GUT. 1994; 36: 76-80
  • 4. Zalewski B. Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features. World J Gastroenterol. 2004; 10(4): 583-5[PubMed]
  • 5. Furuta K, Zahurak M, Goodman SN, Hamilton SR, August JT. CD44 expression in the stromal matrix of colorectal cancer: association with prognosis. Clin Cancer Res. 1998; 4(1): 21-9[PubMed]
  • 6. Kimura Y, Goi T, Nakazawa T, Hirono Y, Katayama K, Urano T, et al. CD44variant exon 9 plays an important role in colon cancer initiating cells. Oncotarget. 2013; 4(5): 785-91[DOI][PubMed]
  • 7. Kunimura T, Yoshida T, Sugiyama T, Morohoshi T. The Relationships Between Loss of Standard CD44 Expression and Lymph Node, Liver Metastasis in T3 Colorectal Carcinoma. J Gastrointest Cancer. 2009; 40(3-4): 115-8[DOI][PubMed]
  • 8. Inoue K, Fry EA. Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer. Genet Epigenet. 2015; 7: 19-32[DOI][PubMed]
  • 9. Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, et al. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int. 2009; 59(4): 241-6[DOI][PubMed]
  • 10. Liu YJ, Yan PS, Li J, Jia JF. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol. 2005; 11(42): 6601-6[PubMed]
  • 11. Bhatavdekar JM, Patel DD, Chikhlikar PR, Trivedi TI, Gosalia NM, Ghosh N, et al. Overexpression of CD44: A useful independent predictor of prognosis in patients with colorectal carcinomas. Ann Surg Oncol. 1998; 5(6): 495-501
  • 12. Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Matsushita K, Kawamura M, et al. Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 2012; 41(5): 1643-52[DOI][PubMed]
  • 13. Wan XB, Pan ZZ, Ren YK, Ding PR, Chen G, Wan DS. Expression and clinical significance of metastasis-related tumor markers in colorectal cancer. Chin J Cancer. 2009; 28(9): 1-6
  • 14. Nihei Z, Ichikawa W, Kojima K, Togo S, Miyanaga T, Hirayama R, et al. The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Surg Today. 1996; 26(9): 760-1[PubMed]
  • 15. Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 2013; 28(1): 9-18[DOI][PubMed]
  • 16. Jackson PA, Green MA, Pouli A, Hubbard R, Marks CG, Cook MG. Relation between stage, grade, proliferation, and expression of p53 and CD44 in adenomas and carcinomas of the colorectum. J Clin Pathol. 1995; 48(12): 1098-101[PubMed]
  • 17. Al-Maghrabi J, Gomaa W, Buhmeida A, Al-Qahtani M, Al-Ahwal M. Decreased immunoexpression of standard form of CD44 is an independent favourable predictor of nodal metastasis in colorectal carcinoma. Anticancer Res. 2012; 32(8): 3455-61[PubMed]
  • 18. Asao T, Nakamura J, Shitara Y, Tsutsumi S, Mochiki E, Shimura T, et al. Loss of standard type of CD44 expression in invaded area as a good indicator of lymph-node metastasis in colorectal carcinoma. Dis Colon Rectum. 2000; 43(9): 1250-4[PubMed]
  • 19. Avoranta ST, Korkeila EA, Syrjanen KJ, Pyrhonen SO, Sundstrom JT. Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence. World J Gastroenterol. 2012; 18(33): 4549-56[DOI][PubMed]
  • 20. Li XD, Ji M, Wu J, Jiang JT, Wu CP. Clinical significance of CD44 variants expression in colorectal cancer. Tumori. 2013; 99(1): 88-92[DOI][PubMed]
  • 21. Rosai J, Ackerman LV. Rosai and Ackerman's surgical pathology. 2011; [DOI][PubMed]
  • 22. World Health Organization . Histological typing of intestinal tumors. 1976;
  • 23. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol. 1999; 52(4): 189-96[PubMed]
  • 24. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. 1994; 54(16): 4539-46[PubMed]
  • 25. Gotley DC, Fawcett J, Walsh MD, Reeder JA, Simmons DL, Antalis TM. Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br J Cancer. 1996; 74(3): 342-51[PubMed]
  • 26. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S, et al. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci. 2000; 910: 106-18[PubMed]
  • 27. Louderbough JM, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res. 2011; 9(12): 1573-86[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments